Canadian radiopharmaceutical firm DraxImage has received Food and Drug Administration clearance to produce and market a radiotherapeutic kit for the preparation of sodium iodide I-131 capsules and oral solution. Sodium iodide I-131 is indicated for the treatment of both thyroid cancer and hyperthyroidism, according to DraxImage parent Draxis Health of Mississauga, Ontario. DraxImage will market the kit in the U.S. through its existing U.S.-based distributors and radiopharmacy suppliers.
By AuntMinnie.com staff writersJanuary 29, 2003
Related Reading
Cytogen, Draxis dispute heats up, January 28, 2003
Production of palladium BrachySeed version halted, January 17, 2003
Draxis Health starts phase I trials, January 9, 2003
Draxis Health’s Q3 revenues climb 10%, November 14, 2002
Copyright © 2003 AuntMinnie.com
